AGL
agilon health Inc
agilon health Inc historical holders
total: 1
Durable Capital Partners agilon health Inc transactions over time
- Total transactions:
- 14
- New positions:
- 2
- Sold out:
- 1
- Added:
- 4
- Reduced:
- 7
- Held since:
- 2026 Q2
- Held for:
- 1 quarter
- Latest activity:
- 2026 Q2
Henry Ellenbogen has been an institutional investor in agilon health Inc (AGL) since 2021 Q2. According to 2026 Q2 report, Henry Ellenbogen holds 440,642 shares with a market value of roughly $47.23M representing 0.46% of their equity portfolio. The fund/company first acquired AGL in 2021 Q2, initially purchasing 247,988 shares. Henry Ellenbogen later completely sold out the position and reinvested in AGL again in 2026 Q2. Since the initial investment, Durable Capital Partners has made 13 more transactions in this position.
Does Henry Ellenbogen still hold AGL?
Yes, Henry Ellenbogen continues to hold agilon health Inc (AGL). According to their 2026 Q2 report, they maintain a position of 440,642 shares valued at approximately $47.23M, representing 0.46% of their equity portfolio.
When did Henry Ellenbogen first invest in AGL?
Henry Ellenbogen first invested in agilon health Inc (AGL) in 2021 Q2 at the reported quarter-end price of $985.45 per share, acquiring 247,988 shares in their initial purchase.
What is Henry Ellenbogen's average cost basis for AGL?
Based on historical transaction data, Henry Ellenbogen's estimated cost basis for agilon health Inc (AGL) is approximately $107.18 per share. This represents their average reported price* across all buy transactions.
Has Henry Ellenbogen reinvested in AGL after selling?
Yes, Henry Ellenbogen has shown renewed interest in agilon health Inc (AGL). After completely selling their position, they reinitiated an investment in 2026 Q2, demonstrating continued conviction in this ticker.
Estimated cost basis*
- Weighted AVG buy price:
- $107.18
AGL transactions history by Durable Capital Partners
14 results
| Period |
% of portfolio |
Shares held after* |
Reported price* |
Value* |
% (shares) of activity |
% change to portfolio |
|---|---|---|---|---|---|---|
|
2026 Q2
|
0.46%
|
440,642
|
$107.18
|
$47,228,010
|
new
|
+0.46%
|
|
2024 Q2
|
0.00%
|
0
|
$152.50
|
|
-100% (-39,045.32)
|
-0.05%
|
|
2024 Q1
|
0.05%
|
39,045.32
|
$152.50
|
$5,954,411
|
-53.28% (-44,525.08)
|
-0.05%
|
|
2023 Q4
|
0.21%
|
83,570.4
|
$313.75
|
$26,220,213
|
-64.06% (-148,969.92)
|
-0.43%
|
|
2023 Q3
|
0.94%
|
232,540.32
|
$444.00
|
$103,247,902
|
-3.68% (-8,884.84)
|
-0.03%
|
|
2023 Q2
|
0.92%
|
241,425.16
|
$433.50
|
$104,657,807
|
+9.68% (+21,299.6)
|
+0.08%
|
|
2023 Q1
|
1.23%
|
220,125.56
|
$593.75
|
$130,699,551
|
-37.77% (-133,583.56)
|
-0.82%
|
|
2022 Q4
|
1.48%
|
353,709.12
|
$403.50
|
$142,721,630
|
-6.22% (-23,453.08)
|
-0.1%
|
|
2022 Q3
|
2.43%
|
377,162.2
|
$585.50
|
$220,828,000
|
+33.99% (+95,685.36)
|
+0.62%
|
|
2022 Q2
|
1.76%
|
281,476.84
|
$545.75
|
$153,616,000
|
+135.39% (+161,898.88)
|
+1.01%
|
|
2022 Q1
|
0.67%
|
$633.75
|
-34.39% (-62,675.44)
|
|||
|
2021 Q4
|
0.96%
|
$675.00
|
-29.32% (-75,601.12)
|
|||
|
2021 Q3
|
1.27%
|
$650.68
|
+3.98% (+9,866.52)
|
|||
|
2021 Q2
|
1.80%
|
$985.45
|
new
|
|||
* Shares, change to shares, sold shares, shares held after: split-adjusted.
* Reported price: this doesn't represent the actual buy or sell price. It is the split-adjusted price of the security as of the last day of the reported period.
If the security is completely sold out, we show the reported split-adjusted price prior to the actual period.
If the security is completely sold out, we show the reported split-adjusted price prior to the actual period.
* Estimated cost basis: based on "Reported price*" (not earlier than 2013 Q2). Calculation starts from the latest "new buy" activity to the latest "close out" activity (if any).
* Value or Price: If the security is completely sold out, we show the reported value (or price) prior to the actual period.
* New buy or own: this means there is no earlier reporting (for us or in general). So we can't know if the actual purchase of the security happened at the reported period or earlier.